Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegoprazan dual therapy for Helicobacter pylori in patients with penicillin allergy or resistance
ChiCTR2500102168Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Putian University
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tegoprazan, furazolidone and tetracycline in Helicobacter pylori infection (2 arms), sponsored by Affiliated Hospital of Putian University. Primary endpoint: Eradication rate. Planned start May 2025; status: not yet recruiting.
02
Drugs
tegoprazanfurazolidonetetracycline
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2500102168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102168.